2020
Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure
Mullan C, Caraballo C, Ravindra NG, Miller PE, McCullough M, Brown K, Aw TW, Gruen J, Clarke JD, Velazquez EJ, Geirsson A, Mori M, Desai NR, Ahmad T. Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure. JACC Heart Failure 2020, 8: 569-577. PMID: 32535119, DOI: 10.1016/j.jchf.2020.03.011.Peer-Reviewed Original ResearchConceptsPsychiatric comorbidityMajor psychiatric illnessNarcotic dependencePsychiatric illnessAdverse eventsHeart failureAlcohol abuseKansas City Cardiomyopathy Questionnaire scoreDrug useVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportAssist device implantationEnd-stage heartRisk of rehospitalizationContinuous-flow LVADRisk of mortalityVulnerable patient populationVentricular assist deviceDevice-related infectionsInteragency RegistryLVAD recipientsSpecific psychiatric conditionsClinical outcomesPatient selectionNeurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices
McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A, Ahmad T, Desai NR. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiology 2020, 5: 175-182. PMID: 31738366, PMCID: PMC6865330, DOI: 10.1001/jamacardio.2019.4965.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy Questionnaire scoreNeurohormonal blockadeAngiotensin receptor blockersVentricular assist deviceQuality of lifeMineralocorticoid antagonistsReceptor blockersHeart failureWalk testQuestionnaire scoresΒ-blockersEnzyme inhibitorsAssist deviceGuideline-directed medical therapyAngiotensin-converting enzyme inhibitorMechanically Assisted Circulatory SupportHeart failure regimenLeft ventricular assist deviceAdvanced heart failureRetrospective cohort analysisContinuous-flow LVADBetter survival rateOutcomes of interestInteragency RegistryTriple therapy
2019
Clinical Implications of the New York Heart Association Classification
Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Piña IL, O'Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical Implications of the New York Heart Association Classification. Journal Of The American Heart Association 2019, 8: e014240. PMID: 31771438, PMCID: PMC6912957, DOI: 10.1161/jaha.119.014240.Peer-Reviewed Original ResearchConceptsNew York Heart Association classificationHF clinical trialsNYHA class IIVentricular ejection fractionGUIDE-ITHeart failureNYHA classWalk distanceEjection fractionRisk stratificationHF-ACTIONAssociation classificationClinical trialsMinute ventilation-carbon dioxide production relationshipKansas City Cardiomyopathy Questionnaire scoreClass IIMulticenter National InstituteNYHA class IIINT-proBNP levelsKaplan-Meier curvesLog-rank testClinical trial eligibilityWilcoxon rank sum testMaximal oxygen uptakeRank sum test